This content was archived on June 19 2014.
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Notice to the reader: This online consultation is now closed. The content found on this page is a snapshot of the live consultation as it was presented to the public during the consultation period.
Health Canada is considering improvements to the Marihuana Medical Access Program (the Program). These proposed changes as they relate to physician-patient interaction are summarized below. More information on Health Canada's proposed changes to the Program is also available.
The improvements being considered would not alter the Program's intent to provide seriously ill Canadians with reasonable access to a legal source of marihuana for medical purposes, where conventional treatments are not appropriate and/or have failed to provide necessary relief.
The core of the redesigned Program would be a new, simplified process in which Health Canada no longer receives applications from program participants. A new supply and distribution system for dried marihuana that relies on licensed commercial producers would be established. These licensed commercial producers, who would be inspected and audited by Health Canada so as to ensure that they comply with all applicable regulatory requirements, would be able to cultivate any strain(s) of marihuana they choose. Finally, the production of marihuana for medical purposes by individuals in homes and communities would be phased out.
Individuals wishing to use marihuana for medical purposes would still be required to consult a physician who is licensed to practice medicine in Canada.
Until any improvements to the Program are in place, the process for applying for an authorization to possess and/or a licence to produce marihuana for medical purposes under the MMAR will remain the same. A detailed transition plan will be shared with stakeholders when proposed regulations are pre-published in Canada Gazette, Part I.
If you are interested in providing comments on this document, please do so by June 30, 2012.
Please note that Health Canada is committed to reviewing and considering all comments received by June 30, 2012.
This information is being collected under the Controlled Drugs and Substances Act and the Marihuana Medical Access Regulations for the purpose of obtaining your views on proposed changes to the Marihuana Medical Access Program (MMAP). To safeguard your privacy, you should ensure that any written comments you provide are sufficiently general that you cannot be identified or re-identified as the author and that other individuals identities are not disclosed. This collection of information is described by the Personal Information Bank on Outreach Activities related to Controlled Drugs and Substances (under development). All personal information created, held or collected by this department is protected under the federal Privacy Act. The Privacy Act also gives you the rights of access to and correction of your personal information. For further information about this Privacy statement please contact Health Canada's Access to Information and Privacy Coordinator. A list of all ATIP Coordinators is available.